Evercore ISI Increases IQVIA (NYSE:IQV) Price Target to $180.00

IQVIA (NYSE:IQV) had its price target increased by Evercore ISI from $170.00 to $180.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Evercore ISI’s target price indicates a potential upside of 8.42% from the company’s current price.

A number of other equities analysts have also recently commented on IQV. JPMorgan Chase & Co. dropped their target price on IQVIA from $232.00 to $177.00 and set an “overweight” rating for the company in a report on Monday, May 19th. Wall Street Zen cut IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Redburn Partners set a $188.00 target price on IQVIA in a report on Friday, May 23rd. Barclays dropped their price objective on IQVIA from $170.00 to $165.00 and set an “equal weight” rating for the company in a report on Wednesday, May 7th. Finally, UBS Group dropped their price objective on IQVIA from $255.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Eight analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $222.45.

IQVIA Stock Performance

NYSE:IQV opened at $166.02 on Wednesday. The company has a debt-to-equity ratio of 2.19, a current ratio of 0.82 and a quick ratio of 0.82. IQVIA has a 1 year low of $134.65 and a 1 year high of $252.88. The stock’s 50 day simple moving average is $151.34 and its two-hundred day simple moving average is $172.74. The company has a market cap of $28.72 billion, a price-to-earnings ratio of 22.62, a PEG ratio of 1.80 and a beta of 1.30.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.63 by $0.07. The firm had revenue of $3.83 billion during the quarter, compared to analysts’ expectations of $3.77 billion. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The company’s quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.54 EPS. As a group, equities analysts anticipate that IQVIA will post 10.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. American National Bank & Trust acquired a new position in IQVIA during the 1st quarter valued at about $26,000. Clal Insurance Enterprises Holdings Ltd grew its stake in IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 131 shares during the last quarter. Golden State Wealth Management LLC grew its stake in IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 130 shares during the last quarter. AllSquare Wealth Management LLC purchased a new stake in IQVIA during the 1st quarter valued at about $33,000. Finally, ST Germain D J Co. Inc. grew its stake in IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 76 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.